Chemical Information
Antiviral agent ID	DrugRepV_6119
Antiviral agent name	FGI-106
IUPAC Name	1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinoline-1,7-diamine;tetrahydrochloride
SMILES (canonical)	CC1=NC2=C(C=CC3=C2C=CC4=C3N=C(C=C4NCCCN(C)C)C)C(=C1)NCCCN(C)C.Cl.Cl.Cl.Cl
Molecular Formula	C28H42Cl4N6
Molecular Weight (g/mol)	604.486
InChl	InChI=1S/C28H38N6.4ClH/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6;;;;/h9-12,17-18H,7-8,13-16H2,1-6H3,(H,29,31)(H,30,32);4*1H
Synonyms	Quino(8,7-H)quinoline-1,7-diamine, N1,N7-bis(3-(dimethylamino)propyl)-3,9-dimethyl-, hydrochloride | 1149348-10-6 | 76TVI971YY
Structural Information
Clinical Information
Biological Information
Secondary Indication	Dengue virus (DENV) 3 NA
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	DC-Sign
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	0.1 MOI
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Post infection
Secondary Indication (Duration of drug delivery)	72 hours (3 days)
Secondary Indication (Drug concentration)	900 nM
Secondary Indication (Cell based assay)	Flow cytometry
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Secondary Indication (Cytotoxicity)	20 μM
Reference	Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S..Development of a broad-spectrum antiviral with activity against Ebola virus..Antiviral Res. 2009 Sep;83(3):245-51. doi: 10.1016/j.antiviral.2009.06.001. Epub 2009 Jun 10. PMID:19523489
Comment	Cell-based assays identified inhibitory activity against diverge virus families, which supports a hypothesis that FGI-106 interferes with a common pathway utilized different viruses.